SCHEMBL3765134

SCHEMBL3765134

CCOc1nc(N)nc2ncc(-c3cnn(CC(C)C)c3)nc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.43
FGFR1 P11362 3/20 0.42
FGFR2 P21802 3/20 0.42
FGFR3 P22607 3/20 0.42
PDPK1 O15530 1/20 0.41
PIK3CA P42336 1/20 0.41
PIM1 P11309 1/20 0.38
PIM3 Q86V86 1/20 0.38
PIM2 Q9P1W9 1/20 0.38
NOS1 P29475 7/20 0.38
FGFR4 P22455 2/20 0.36
KDR P35968 1/20 0.36
KDM5B Q9UGL1 2/20 0.36
TTK P33981 1/20 0.35
MAPK8 P45983 1/20 0.35
SYK P43405 1/20 0.35
ABL1 P00519 1/20 0.35
BCR P11274 1/20 0.35
PIK3CG P48736 1/20 0.34
KDM5A P29375 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3760316 0.89 KDM5B (0.38) MAPK1FGFR1FGFR2FGFR3PDPK1
SCHEMBL3760900 0.87 MAPK1 (0.43) MAPK1FGFR1FGFR2FGFR3PIK3CA
SCHEMBL3757193 0.83 CSF1R (0.44) MAPK1FGFR1FGFR2FGFR3NOS1
SCHEMBL3757974 0.82 ADORA2A (0.45) MAPK1PIK3CANOS1PIK3CGATR
SCHEMBL3757137 0.81 IKBKE (0.46) FGFR1FGFR2FGFR3NOS1FGFR4
SCHEMBL3760475 0.77 NOS1 (0.45) MAPK1PIK3CANOS1PIK3CG
SCHEMBL3765398 0.76 NOS1 (0.47) PIK3CANOS1PIK3CG
SCHEMBL3763426 0.76 NOS1 (0.61) MAPK1FGFR1FGFR2FGFR3PIK3CA
SCHEMBL3757302 0.76 NOS1 (0.44) MAPK1PIK3CANOS1PIK3CG
SCHEMBL3766265 0.76 NOS1 (0.48) PIK3CANOS1PIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190152974-A1 SUBSTITUTED PTERIDINES USEFUL FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS GILEAD SCIENCES, INC. 2019-05-23 US claimed
US-20100305117-A1 SUBSTITUTED PTERIDINES USEFUL FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2010-12-02 US claimed
WO-2008009079-A2 SUBSTITUTED PTERIDINES USEFUL FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 WO claimed
US-20190152974-A1 SUBSTITUTED PTERIDINES USEFUL FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS GILEAD SCIENCES, INC. 2019-05-23 US disclosed
US-10144736-B2 Substituted pteridines useful for the treatment and prevention of viral infections GILEAD SCIENCES, INC. (US) 2018-12-04 US disclosed
US-20100305117-A1 SUBSTITUTED PTERIDINES USEFUL FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2010-12-02 US disclosed
WO-2008009079-A2 SUBSTITUTED PTERIDINES USEFUL FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190152974-A1 SUBSTITUTED PTERIDINES USEFUL FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS HCCS, DPYD, HAVCR2 MAPK1 3866/4885FGFR1 2326/4885FGFR2 2738/4885
US-10144736-B2 Substituted pteridines useful for the treatment and prevention of viral infections HCCS, DPYD, HAVCR2 MAPK1 3866/4885FGFR1 2326/4885FGFR2 2738/4885
US-20100305117-A1 SUBSTITUTED PTERIDINES USEFUL FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS HCCS, DPYD, HAVCR2 MAPK1 3866/4885FGFR1 2326/4885FGFR2 2738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.